Quest Diagnostics

Report Status: Final

Smith, John

Patient Information	Specimen Information	Client Information
[redacted] **DOB:** [redacted] **AGE:** [redacted] Gender: M Fasting: Y Phone: [redacted] Patient ID: [redacted]	Specimen: HL338541E Requisition: 0000120 Collected: 03/16/2018 / 08:08 CDT Received: 03/17/2018 / 00:40 CDT Reported: 03/21/2018 / 20:00 CDT	Client #: [redacted] [redacted]

COMMENTS: FASTING:YES

Test Name	In Range	Out Of Range	Reference Range	Lab
CBC (INCLUDES DIFF/PLT)				RGA
WHITE BLOOD CELL COUNT	9.6		3.8-10.8 Thousand/uL	
RED BLOOD CELL COUNT	5.69		4.20-5.80 Million/uL	
HEMOGLOBIN	16.4		13.2-17.1 g/dL	
HEMATOCRIT	47.7		38.5-50.0 %	
MCV	83.8		80.0-100.0 fL	
MCH	28.8		27.0-33.0 pg	
MCHC	34.4		32.0-36.0 g/dL	
RDW	13.9		11.0-15.0 %	
PLATELET COUNT	330		140-400 Thousand/uL	
MPV	10.2		7.5-12.5 fL	
ABSOLUTE NEUTROPHILS	5510		1500-7800 cells/uL	
ABSOLUTE LYMPHOCYTES	2957		850-3900 cells/uL	
ABSOLUTE MONOCYTES	758		200-950 cells/uL	
ABSOLUTE EOSINOPHILS	250		15-500 cells/uL	
ABSOLUTE BASOPHILS	125		0-200 cells/uL	
NEUTROPHILS	57.4		%	
LYMPHOCYTES	30.8		%	
MONOCYTES	7.9		%	
EOSINOPHILS	2.6		%	
BASOPHILS	1.3		%	
PSA, TOTAL	0.5		< OR = 4.0 ng/mL	RGA

The total PSA value from this assay system is standardized against the WHO standard. The test result will be approximately 20% lower when compared to the equimolar-standardized total PSA (Beckman Coulter). Comparison of serial PSA results should be interpreted with this fact in mind.

This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not be interpreted as absolute evidence of the presence or absence of disease.

TESTOSTERONE,FR(DIALYSIS) AND TOTAL(LC/MS/MS)				SLI
TESTOSTERONE, TOTAL, LC/MS/MS		246 L	250-1100 ng/dL	
FREE TESTOSTERONE	48.5		35.0-155.0 pg/mL	

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has not been cleared or approved by the US Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

PERFORMING SITE:

RGA QUEST DIAGNOSTICS HOUSTON, 5850 ROGERDALE ROAD, HOUSTON, TX 77072-1602 Laboratory Director: JULIA KENNY, M.D., CLIA: 45D0660150
SLI QUEST DIAGNOSTICS NICHOLS VALENCIA, 27027 TOURNEY ROAD, VALENCIA, CA 91355-5386 Laboratory Director: JON M NAKAMOTO,MD,PHD, CLIA: 05D0550302

Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics.